<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Phenotypically distinct human B cell lines display two transcriptionally distinct forms of Epstein-Barr virus (EBV) latency </plain></SENT>
<SENT sid="1" pm="."><plain>Latency I (Lat I) in group I Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines is characterized by selective expression of the virus-coded nuclear antigen EBNA 1 from a uniquely spliced <z:chebi fb="2" ids="33699">mRNA</z:chebi> driven by the Fp promoter </plain></SENT>
<SENT sid="2" pm="."><plain>Latency III (Lat III) in group III <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and EBV-transformed lymphoblastoid cell lines (LCLs) is characterized by expression of EBNAs 1, 2, 3a, 3b, 3c, and -LP from <z:chebi fb="2" ids="33699">mRNAs</z:chebi> driven by the Cp or Wp promoter and of the latent membrane proteins (LMPs 1, 2A, and 2B) from <z:chebi fb="2" ids="33699">mRNAs</z:chebi> driven by the LMP promoters </plain></SENT>
<SENT sid="3" pm="."><plain>Here we have altered the group I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and LCL phenotypes by cell hybridization and screened for attendant changes in EBV latency by PCR analysis of <z:mp ids='MP_0001799'>viral</z:mp> <z:chebi fb="2" ids="33699">mRNAs</z:chebi> and immunoblotting of <z:mp ids='MP_0001799'>viral</z:mp> proteins </plain></SENT>
<SENT sid="4" pm="."><plain>Fusion of group I <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells with LCLs activated the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> virus genome from a Lat I to Lat III pattern of gene expression </plain></SENT>
<SENT sid="5" pm="."><plain>Fusion of LCLs with nonlymphoid lines repressed virus gene expression from Lat III either to Lat I or to another form of latency (Lat II) hitherto not seen in vitro and characterized by selective expression of the Fp-driven EBNA 1 mRNA and of the LMP 1, 2A, and 2B transcripts </plain></SENT>
<SENT sid="6" pm="."><plain>There are therefore three forms of EBV latency which can be interconverted by altering <z:mp ids='MP_0005384'>cellular phenotype</z:mp> and thereby virus promoter usage </plain></SENT>
</text></document>